The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Oct. 22, 2020
Applicant:
Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;
Inventors:
Dirk Kessler, Vienna, AT;
Christiane Kofink, Perchtoldsdorf, AT;
Matthew Russell Netherton, Danbury, CT (US);
Juergen Ramharter, Vienna, AT;
Tobias Wunberg, Hinterbruehl, AT;
Assignee:
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 9/20 (2006.01); A61K 31/337 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/7068 (2006.01); A61P 35/00 (2006.01); C07D 239/94 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/10 (2006.01); C07D 413/10 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 31/337 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/7068 (2013.01); A61P 35/00 (2018.01); C07D 239/94 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/10 (2013.01); C07D 413/10 (2013.01); C07D 487/04 (2013.01);
Abstract
The present invention encompasses compounds of formula (I) wherein the groups Rto Rhave the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.